memantine
memantine: developed by 4 companies · 7 clinical trials tracked · 5 FDA decisions.
memantine evidence translation
What we can confirm
5 FDA records · 7 tracked trials
What it means
What to watch
Prepared research question
What is verified about memantine, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 2 study sponsors
Development Pipeline (4)
| Company | Phase |
|---|---|
| AbbVie Inc. (ABBV) | Approved |
| ANI PHARMACEUTICALS INC (ANIP) | Approved |
| DR REDDYS LABORATORIES LTD (RDY) | Approved |
| Teva Pharmaceutical Industries Limited (TEVA) | Approved |
Clinical Trials (7)
A Randomized Phase 2 Trial of Memory Avoidance Whole Brain Radiotherapy Versus Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)
Primary endpoint: Time to neurocognitive failure (NCF)
COMPARATIVE STUDY TO EVALUATE SATISFACTION WITH THE USE OF ORODISPERSIBLE MEMANTINE TABLETS VERSUS CONVENTIONAL TABLETS IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER'S DISEASE: A PHASE IV, RANDOMIZED, OPEN-LABEL STUDY.
Primary endpoint: Caregiver treatment satisfaction assessed by the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q)
A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors
Primary endpoint: The mean slope of the Cogstate composite Z score (an average of detection, Identification, and one-back Z scores, each Z score calculated using Cogstate age-based normative data)
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia
Primary endpoint: Positive & Negative Symptom Scale total (PANSSt)
Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Brain Metastases From Small Cell Lung Cancer
Primary endpoint: Time to neurocognitive failure
A Randomized Placebo-controlled, Double Blind Phase 2 Clinical Trial of Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus
Primary endpoint: Repeatable Battery for Assessment of Neuropsychological Status (RBANS) Total Index Score at endpoint (Visit 4)
Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors: A Pilot Study
Primary endpoint: Percent of Approached Participants Who Consent to Study Participation
FDA Decisions5 records
Frequently asked questions
Who is developing memantine?
memantine is being developed by AbbVie Inc., ANI PHARMACEUTICALS INC, DR REDDYS LABORATORIES LTD and 1 other.
How many clinical trials involve memantine?
BioSniper tracks 7 clinical trials involving memantine.
What is memantine's latest FDA decision?
The most recent tracked FDA decision for memantine is Approval, dated December 15, 2023.